Modified IWG 2000 erythroid response to lenalidomide
| Variable . | Continuous daily dosing, n = 100* . | 21-day dosing, n = 114* . | All patients, n = 214 . |
|---|---|---|---|
| Erythroid response, no (%) [95% CI] | |||
| Transfusion independence and 10 g/L Hb or more increase | 27 (27) | 29 (25) | 56 (26) [20-33] |
| 50% or greater decrease in no. of transfusions | 15 (15) | 22 (19) | 37 (17) [12-23] |
| Total transfusion response | 42 (42) | 51 (45) | 93 (43) [37-50] |
| Median time to transfusion independence, wk (range) | 7.4 (1-24) | 4.1 (1-39) | 4.8 (1-39) |
| Hemoglobin, g/L | |||
| Baseline, median (range)† | 79 (62-97) | 81 (61-106) | 80 (61-106) |
| Response, median (range)‡ | 116 (91-168) | 110 (73-180) | 116 (73-180) |
| Increase, median (range) | 33 (15-92) | 31 (10-98) | 32 (10-98) |
| Variable . | Continuous daily dosing, n = 100* . | 21-day dosing, n = 114* . | All patients, n = 214 . |
|---|---|---|---|
| Erythroid response, no (%) [95% CI] | |||
| Transfusion independence and 10 g/L Hb or more increase | 27 (27) | 29 (25) | 56 (26) [20-33] |
| 50% or greater decrease in no. of transfusions | 15 (15) | 22 (19) | 37 (17) [12-23] |
| Total transfusion response | 42 (42) | 51 (45) | 93 (43) [37-50] |
| Median time to transfusion independence, wk (range) | 7.4 (1-24) | 4.1 (1-39) | 4.8 (1-39) |
| Hemoglobin, g/L | |||
| Baseline, median (range)† | 79 (62-97) | 81 (61-106) | 80 (61-106) |
| Response, median (range)‡ | 116 (91-168) | 110 (73-180) | 116 (73-180) |
| Increase, median (range) | 33 (15-92) | 31 (10-98) | 32 (10-98) |